Invention Grant
US09573988B2 Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
有权
使用抗CD123嵌合抗原受体工程化T细胞有效靶向原发性人类白血病
- Patent Title: Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
- Patent Title (中): 使用抗CD123嵌合抗原受体工程化T细胞有效靶向原发性人类白血病
-
Application No.: US14184895Application Date: 2014-02-20
-
Publication No.: US09573988B2Publication Date: 2017-02-21
- Inventor: Jennifer Brogdon , Saar Gill , Carl H. June , Michael D. Kalos , Andreas Loew , John Scholler
- Applicant: Jennifer Brogdon , Saar Gill , Carl H. June , Michael D. Kalos , Andreas Loew , John Scholler
- Applicant Address: CH Basel US PA Philadelphia
- Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee Address: CH Basel US PA Philadelphia
- Agency: Lando & Anastasi, LLP
- Main IPC: C12N15/62
- IPC: C12N15/62 ; C12N15/63 ; C07K16/28 ; C07K14/705 ; C07K14/725 ; A61K39/00
Abstract:
The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
Public/Granted literature
Information query
IPC分类:
